Setara Biosciences launched with $90 million in funding and put a lead small-molecule program into the clinic. The company’s initial focus includes Charcot-Marie-Tooth disease type 2C, a rare neuromuscular disorder. Setara’s lead asset also targets overactive bladder, positioning the early-stage portfolio across an orphan indication and a broader, more prevalent condition. The molecule traces back to Actio Biosciences, which Jazz Pharmaceuticals acquired, creating an example of how large pharma can incubate and then re-route platform assets into new-company development. With the investment backing clinical entry, Setara is now set to generate early human proof-of-mechanism and safety data that will determine how quickly it can advance toward registrational path selection.